ERBB2 and cancer: Despite lower overall ERBB2 expression, HER2-HET tumors retained levels of PI3K/ERBB pathway activation equivalent to those in non-HET/pCR cancers, likely due to increased expression of downstream pathway components including MYC and EIF4EBP1.